These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 29500302)

  • 1. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.
    Kretzschmar B; Pellkofer H; Weber MS
    Curr Neurol Neurosci Rep; 2016 Apr; 16(4):38. PubMed ID: 26944956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Emerging therapies for multiple sclerosis].
    de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
    Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New oral drugs for the treatment of multiple sclerosis.
    Chard D; Trip A; Chataway J
    Br J Hosp Med (Lond); 2016 Sep; 77(9):502-3. PubMed ID: 27640651
    [No Abstract]   [Full Text] [Related]  

  • 5. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
    di Nuzzo L; Orlando R; Nasca C; Nicoletti F
    Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponesimod (Ponvory) for multiple sclerosis.
    Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110
    [No Abstract]   [Full Text] [Related]  

  • 10. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.
    Nixon R; Bergvall N; Tomic D; Sfikas N; Cutter G; Giovannoni G
    Adv Ther; 2014 Nov; 31(11):1134-54. PubMed ID: 25414048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T; Kubala Havrdova E; Horakova D; Izquierdo G; Prat A; Girard M; Duquette P; Grammond P; Onofrj M; Lugaresi A; Ozakbas S; Kappos L; Kuhle J; Terzi M; Lechner-Scott J; Boz C; Grand'Maison F; Prevost J; Sola P; Ferraro D; Granella F; Trojano M; Bergamaschi R; Pucci E; Turkoglu R; McCombe PA; Pesch VV; Van Wijmeersch B; Solaro C; Ramo-Tello C; Slee M; Alroughani R; Yamout B; Shaygannejad V; Spitaleri D; Sánchez-Menoyo JL; Ampapa R; Hodgkinson S; Karabudak R; Butler E; Vucic S; Jokubaitis V; Spelman T; Butzkueven H
    J Neurol Neurosurg Psychiatry; 2019 Apr; 90(4):458-468. PubMed ID: 30636699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of action of three newly registered drugs for multiple sclerosis treatment.
    Kasarełło K; Cudnoch-Jędrzejewska A; Członkowski A; Mirowska-Guzel D
    Pharmacol Rep; 2017 Aug; 69(4):702-708. PubMed ID: 28550802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
    Guarnera C; Bramanti P; Mazzon E
    Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to oral disease-modifying therapy in multiple sclerosis patients: A systematic review.
    Yoon EL; Cheong WL
    Mult Scler Relat Disord; 2019 Feb; 28():104-108. PubMed ID: 30590239
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-life use of oral disease-modifying treatments in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    Acta Neurol Scand; 2019 Jul; 140(1):32-39. PubMed ID: 30958901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral agents in multiple sclerosis.
    Lorefice L; Fenu G; Frau J; Coghe GC; Marrosu MG; Cocco E
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):15-25. PubMed ID: 25924620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of novel therapeutic agents for the treatment of multiple sclerosis: a brief overview.
    Mulakayala N; Rao P; Iqbal J; Bandichhor R; Oruganti S
    Eur J Med Chem; 2013 Feb; 60():170-86. PubMed ID: 23291119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel Agents for Relapsing Forms of Multiple Sclerosis.
    Straus Farber R; Harel A; Lublin F
    Annu Rev Med; 2016; 67():309-21. PubMed ID: 26394285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P; Martinelli V; Pfleger C; Rieckmann P; Alonso-Magdalena L; Galazka A; Dangond F; Phillips L
    Clin Ther; 2019 Feb; 41(2):249-260.e18. PubMed ID: 30846120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in oral immunomodulating therapies in relapsing multiple sclerosis.
    Derfuss T; Mehling M; Papadopoulou A; Bar-Or A; Cohen JA; Kappos L
    Lancet Neurol; 2020 Apr; 19(4):336-347. PubMed ID: 32059809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.